Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Matthias M. Heck"'
Autor:
Fabian Falkenbach, Francesca Ambrosini, Pierre Tennstedt, Matthias Eiber, Matthias M. Heck, Felix Preisser, Markus Graefen, Lars Budäus, Daniel Koehler, Sophie Knipper, Tobias Maurer
Publikováno v:
Cancers, Vol 15, Iss 20, p 5008 (2023)
Objective: To assess the influence of biochemical recurrence (BCR) risk groups and PSA kinetics on the outcomes of radioguided surgery against prostate-specific membrane antigen (PSMA-RGS). Currently, neither BCR risk group nor PSA doubling time (PSA
Externí odkaz:
https://doaj.org/article/90859074f606438f9a4a97aa7dcdfe8e
Autor:
Nina N. Harke, Christian Wagner, Robert M. Hermann, Boris A. Hadaschik, Jan Philipp Radtke, Alev Altay-Langguth, Stefan Aufderklamm, Christian Bach, Martina Becker-Schiebe, Andreas Blana, Frank Bruns, Stephan Buse, Stephanie E. Combs, Christina L. Engels, Emad Ezzibdeh, Marcel Fiedler, Laura-Anna Fischer, Mahmoud Farzat, Alexander Frismann, Matthias M. Heck, Christoph Henkenberens, Marie C. Roesch, Christoph Käding, Gunther Klautke, Philipp Krausewitz, Markus A. Kuczyk, Conrad Leitsmann, Sebastian Lettmaier, Samy Mahjoub, Andreas Manseck, Daniel Medenwald, Andreas Meyer, Oliver Micke, Rudolf Moritz, Marcel Ott, Inga Peters, Sasa Pokupic, Daniel Porres, Felix Preisser, Kathrin Reichel, Andreas Schneider, Christian Schwentner, Sergiu Scobioala, Michael Truss, Daniel Wegener, Felix Wezel, Kay Willborn, Jörn H. Witt, Andrea Wittig, Michael Wittlinger, Hendrik A. Wolff, Volker Zimmermanns, Hans Christiansen
Publikováno v:
PLoS ONE, Vol 17, Iss 6 (2022)
Introduction Since the beginning of the pandemic in 2020, COVID-19 has changed the medical landscape. International recommendations for localized prostate cancer (PCa) include deferred treatment and adjusted therapeutic routines. Materials and method
Externí odkaz:
https://doaj.org/article/12ece23db50445d8b382e07e29f1afb3
Autor:
Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, Jan Neumann, Gregor Miller, Wolfgang Weber, Jürgen E. Gschwend, Matthias Eiber, Matthias M. Heck
Publikováno v:
European Urology. 82:156-160
Autor:
Roman Nawroth, Jürgen E. Gschwend, Kathleen Herkommer, Mark Thalgott, Tobias Maurer, Hubert Kübler, Michael Autenrieth, Tibor Schuster, Gregor Weirich, Elisabeth Vitzthum, Marc Souchay, Miriam Bandur, Margitta Retz, Matthias M. Heck
Supplemental Table 1: A) Multivariable analysis for the association with biochemical recurrence comparing histopathologic and molecular lymph node status as categorical variables excluding 7 patients receiving adjuvant treatment for pN1-disease B) Mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::370b87001874934b8cff9d880a434ee4
https://doi.org/10.1158/1078-0432.22470282
https://doi.org/10.1158/1078-0432.22470282
Autor:
Roman Nawroth, Jürgen E. Gschwend, Kathleen Herkommer, Mark Thalgott, Tobias Maurer, Hubert Kübler, Michael Autenrieth, Tibor Schuster, Gregor Weirich, Elisabeth Vitzthum, Marc Souchay, Miriam Bandur, Margitta Retz, Matthias M. Heck
Purpose: Molecular lymph node (LN) analysis using quantitative polymerase chain reaction (qPCR) detects LN metastases with higher sensitivity than histopathology. However, the prognostic role of molecular LN status in prostate cancer patients treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88259932a2e0edf69975118e895c8810
https://doi.org/10.1158/1078-0432.c.6527499.v1
https://doi.org/10.1158/1078-0432.c.6527499.v1
Autor:
Lukas Lunger, Lisa Steinhelfer, Philipp Korn, Matthias Eiber, Tobias Maurer, Jakob Büchler, Thomas Horn, Jürgen E. Gschwend, Matthias M. Heck
Publikováno v:
European urology oncology.
Lymph node metastases (LNMs) are common in intermediate- to high-risk prostate cancer (PC) and may be missed during extended pelvic lymph node dissection (ePLND). Here we report on the use of prostate-specific membrane antigen (PSMA)-radioguided surg
Autor:
Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, Daniel Koehler, Isabel Rauscher, Matthias Eiber, Fijs W.B. van Leeuwen, Pim van Leeuwen, Hilda de Barros, Henk van der Poel, Lars Budäus, Thomas Steuber, Markus Graefen, Pierre Tennstedt, Matthias M. Heck, Thomas Horn, Tobias Maurer
Publikováno v:
European urology.
In a subset of patients with recurrent oligometastatic prostate cancer (PCa) salvage surgery with prostate-specific membrane antigen (PSMA)-targeted radioguidance (PSMA-RGS) might be of value.To evaluate the oncological outcomes of salvage PSMA-RGS a
Publikováno v:
European Urology. 81:e117
Autor:
Maythinee, Chantadisai, Gabriel, Buschner, Markus, Krönke, Isabel, Rauscher, Thomas, Langbein, Stephan G, Nekolla, Kilian, Schiller, Matthias M, Heck, Tobias, Maurer, Alexander, Wurzer, Hans-Juergen, Wester, Calogero, D'Alessandria, Wolfgang, Weber, Matthias, Eiber
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 62(7)
The objective of this retrospective study was to assess the detection rate (DR), positive predictive value (PPV), and correct detection rate (CDR) of
Autor:
Andrei, Gafita, Matthias M, Heck, Isabel, Rauscher, Robert, Tauber, Lisena, Cala, Charlott, Franz, Calogero, D'Alessandria, Margitta, Retz, Wolfgang A, Weber, Matthias, Eiber
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 61(10)
Prostate-specific antigen (PSA) is widely used to monitor treatment response in patients with metastatic castration-resistant prostate cancer. However, PSA measurements are considered only after 12 wk of treatment. We aimed to evaluate the prognostic